FeetMe

High-Level Overview

FeetMe is a Paris-based digital health company founded in 2013 that develops smart connected insoles equipped with pressure sensors for real-time gait, activity, and mobility assessments in clinical and real-world settings.[1][2][4] The company serves physicians, clinicians, patients with mobility impairments, and pharmaceutical trials by providing medical wearables and digital health services to monitor and improve walking, running, and overall foot health, addressing challenges like disease management and rehabilitation.[1][2][5] With 71 employees, $27.7 million in revenue, and $12.9 million in total funding—including a €9.4 million Series A in 2021 led by LBO France—FeetMe demonstrates strong growth momentum in the medical device sector.[2]

Origin Story

FeetMe was founded in 2013 in Paris, France, by a team of engineers, clinicians, and designers focused on mobility care, with Andrey Mostovov serving as Chief Technology Officer.[2][3][4][5] The idea emerged from the need for precise, real-world tools to assess gait and activity, leading to the development of digital insoles with pressure sensors for foot health analysis.[1][4] Early traction came through product innovation and funding, culminating in a pivotal €9.4 million Series A round in 2021 from investors including LBO France, Kurma Diagnostics, Paris Saclay seed fund, Idinvest Partners, Seventure, and SOSV, which accelerated commercial activities in clinical trials.[2]

Core Differentiators

• Unique Technology Platform: High-quality connected insoles with pressure sensors enable precise in-clinic and real-world gait, activity, and toe-off detection analysis, distinguishing FeetMe in digital health wearables.[1][3][4]
• Comprehensive Mobility Solutions: Combines hardware (smart insoles) with digital health services for rehabilitation, disease management, and pharmaceutical clinical trials, supporting physicians and patients in keeping people walking better.[2][5]
• Innovation Pipeline: Active patents in areas like timestamped data synchronization, training monitoring, insole calibration, and transport cases underscore ongoing R&D leadership as of 2025.[3]
• Proven Scale: 71 employees, $27.7M revenue, and $12.9M funding reflect commercial viability and investor confidence in a competitive medtech landscape.[2]

Role in the Broader Tech Landscape

FeetMe rides the wave of digital therapeutics and wearable medtech, capitalizing on trends in AI-driven health data analytics, remote patient monitoring, and personalized rehabilitation amid aging populations and chronic mobility disorders.[1][3] Timing aligns with post-pandemic demand for real-world evidence in clinical trials and value-based care, where precise gait metrics inform pharma outcomes and reduce healthcare costs.[2] Market forces like EU medtech regulations and rising AI integration favor FeetMe's sensor tech, positioning it to influence the ecosystem by enabling better mobility interventions and data for drug development.[3][6]

Quick Take & Future Outlook

FeetMe is poised for expansion through new digital health services, deeper pharma partnerships, and global commercialization of its insole platform, leveraging 2025 patents for enhanced AI analytics.[2][3] Trends like wearable AI integration and real-world data mandates will propel growth, potentially leading to Series B funding or acquisition by larger medtech players. As mobility tech evolves, FeetMe's clinician-focused innovations will amplify its role in transforming gait assessment from reactive to predictive care, building on its foundation as a leader in smart insoles for sustained walking better.